3 Fabulous Dividend Stocks to Buy in February
February is the shortest month, but that doesn't mean income investors don't have much time to find great stocks. Three Motley Fool contributors believe they have identified fabulous dividend stocks to buy this month. Here's why they like (NYSE: ABBV), Amgen (NASDAQ: AMGN), and Gilead Sciences (NASDAQ: GILD).
Keith Speights (AbbVie): AbbVie has been a longtime favorite for income investors. The big drugmaker's 52 consecutive years of dividend increases (including when it was part of Abbott) qualify it as a Dividend King. Its forward dividend yield is a juicy 3.4%.
For a while, though, AbbVie might not have been viewed as a fabulous pick by many investors. Humira, the company's top-selling drug for years, lost U.S. patent exclusivity in early 2023. As a result, revenue and profits began to sink.
Source Fool.com
AbbVie Inc. Aktie
Mit 38 Buy-Einschätzungen und keiner einzigen Sell-Einschätzung ist AbbVie Inc. einer der Lieblinge unserere Community.
Das von der Community festgelegte Kursziel von 209 € für AbbVie Inc. deutet auf ein leichtes Wachstumspotenzial im Vergleich zu 190.8 € hin.
